4.6 Article

Using extensional flow to reveal diverse aggregation landscapes for three IgG1 molecules

期刊

BIOTECHNOLOGY AND BIOENGINEERING
卷 115, 期 5, 页码 1216-1225

出版社

WILEY
DOI: 10.1002/bit.26543

关键词

aggregation; antibody; bioprocessing; extensional flow; shear flow

资金

  1. EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, UK [EP/I033270/1]
  2. ERC [FP7/2007-2013, 32240]
  3. University of Leeds
  4. Medimmune Ltd
  5. GSK
  6. Royal Academy of Engineering
  7. Engineering and Physical Sciences Research Council [1511303] Funding Source: researchfish

向作者/读者索取更多资源

Monoclonal antibodies (mAbs) currently dominate the biopharmaceutical sector due to their potency and efficacy against a range of disease targets. These proteinaceous therapeutics are, however, susceptible to unfolding, mis-folding, and aggregation by environmental perturbations. Aggregation thus poses an enormous challenge to biopharmaceutical development, production, formulation, and storage. Hydrodynamic forces have also been linked to aggregation, but the ability of different flow fields (e.g., shear and extensional flow) to trigger aggregation has remained unclear. To address this question, we previously developed a device that allows the degree of extensional flow to be controlled. Using this device we demonstrated that mAbs are particularly sensitive to the force exerted as a result of this flow-field. Here, to investigate the utility of this device to bio-process/biopharmaceutical development, we quantify the effects of the flow field and protein concentration on the aggregation of three mAbs. We show that the response surface of mAbs is distinct from that of bovine serum albumin (BSA) and also that mAbs of similar sequence display diverse sensitivity to hydrodynamic flow. Finally, we show that flow-induced aggregation of each mAb is ameliorated by different buffers, opening up the possibility of using the device as a formulation tool. Perturbation of the native state by extensional flow may thus allow identification of aggregation-resistant mAb candidates, their bio-process parameters and formulation to be optimized earlier in the drug-discovery pipeline using sub-milligram quantities of material.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据